To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion
NCT04814056
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
15
Enrollment
OTHER
Sponsor class
Conditions
NRG1-fused Non-small Cell Lung Cancer
Interventions
DRUG:
Afatinib Dimaleate
Sponsor
Shanghai Chest Hospital